A familiar story ... https://t.co/FFRjzM2piB
In depth analysis of the recent CRISPR decision - and why this is a story that is probably not yet over. https://t.co/ea2uMZFT2S
The gene-editing tool CRISPR is in the process of transforming the life sciences industry. Perhaps not surprisingly with such a revolutionary technology still in its relative infancy, a dispute over patents between universities and research institutes that have been at the forefront of its development, erupted over just who owns some of the foundational IP. Last week in a closely watched...
Microsoft recently filed a petition for inter partes review of a patent owned by Philips – one that is among several that the Dutch company is currently asserting in US district court against a number of Chinese, Taiwanese and US manufacturers. As reported by Steve Brachmann over at the IP Watchdog blog yesterday, Microsoft filed a petition with the USPTO’s Patent Trials...
In what it hailed as a “landmark” biotech patent validity case, Danish company Novozymes has won out in a six year patent fight with major Chinese competitors following a judgment from the Supreme People’s Court. The result is important because Novozymes has said that some of the patentability requirements in its technology area are harder to meet in China compared...
Licence on transfer is an emerging and flexible licensing tool which should be a part of every corporate IP transactions strategy
James Kovacs and Nader Mousavi
IAM Patent 1000
The definitive guide to leading patent lawyers, attorneys and firms in over 40 jurisdictions, with a special section on expert witnesses in the United States.Visit site